---
title: Factors Affecting Attachment Loss in Clear Aligner Treatment
nct_id: NCT07352644
overall_status: COMPLETED
phase: NA
sponsor: Bezmialem Vakif University
study_type: INTERVENTIONAL
primary_condition: Malocclusion
countries: Turkey (Türkiye)
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT07352644.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT07352644"
ct_last_update_post_date: 2026-01-20
last_seen_at: "2026-05-12T07:22:44.113Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Factors Affecting Attachment Loss in Clear Aligner Treatment

**Official Title:** Factors Affecting Attachment Loss in Clear Aligner Treatment: A Prospective Clinical Study

**NCT ID:** [NCT07352644](https://clinicaltrials.gov/study/NCT07352644)

## Key Facts

- **Status:** COMPLETED
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 4
- **Lead Sponsor:** Bezmialem Vakif University
- **Conditions:** Malocclusion, Crowded Teeth, Attachment
- **Start Date:** 2022-01-01
- **Completion Date:** 2022-06-01
- **CT.gov Last Update:** 2026-01-20

## Brief Summary

This prospective clinical study evaluated the incidence of composite attachment loss in patients undergoing clear aligner treatment and identified patient-, tooth-, and treatment-related factors associated with attachment debonding. Twenty-one patients were followed for six months, and attachment failures were recorded at routine visits. Outcomes were compared according to attachment type (conventional vs. optimized), attachment size, tooth type, dental arch, and patient-related factors.

## Detailed Description

Composite attachments are integral to clear aligner therapy for improving force delivery, retention, and control of complex tooth movements. Despite their biomechanical importance, attachment loss remains a common clinical challenge and may compromise treatment efficiency and predictability. In this prospective study, attachments were bonded following the manufacturer's protocol using a high-viscosity composite. Patients were followed for six months, and attachment failures were documented with respect to type, size, tooth position, and patient-related behaviors. The primary objective was to determine the incidence of attachment loss and to identify factors associated with debonding, thereby contributing to clinical strategies that may reduce attachment failure and enhance treatment outcomes.

## Eligibility

- **Minimum age:** 12 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

Permanent dentition. Mild to moderate crowding. No history of previous orthodontic treatment with fixed appliances or clear aligners

Exclusion Criteria:

Poor oral health. Bruxism. Crown restorations. Dental fluorosis. Enamel hypoplasia or other structural abnormalities affecting attachment bonding
```

## Arms

- **Clear Aligner Treatment** (EXPERIMENTAL) — Participants received clear aligner therapy (Invisalign®) with composite attachments bonded according to the manufacturer's protocol. Both conventional and optimized attachment types were used as part of the planned orthodontic treatment, and attachment loss was prospectively evaluated over a 6-month follow-up period.

## Interventions

- **Clear Aligners with Composite Attachments** (DEVICE) — Participants received clear aligner therapy (Invisalign®, Align Technology, San Jose, CA, USA). Composite attachments were bonded according to the manufacturer's protocol using a high-viscosity composite. Both conventional and optimized attachment types were used as part of the planned orthodontic treatment, and attachment loss was prospectively evaluated during a 6-month follow-up period.

## Primary Outcomes

- **Attachment Loss Rate** _(time frame: 6 months)_ — Proportion of composite attachments exhibiting complete detachment or partial debonding (irregular residual composite) during routine follow-up visits. Attachment loss was assessed by direct intraoral examination and tactile verification using a dental explorer.

## Locations (1)

- Bezmialem Vakif University, Istanbul, Turkey (Türkiye)

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.bezmialem vakif university|istanbul||turkey (türkiye)` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT07352644.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT07352644*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*